InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
2H2 Free
04/10/24 11:10 AM
profile icon
Monksdream PremiumMember
02/23/24 4:22 PM
profile icon
2H2 Free
02/23/24 4:17 PM
profile icon
Monksdream PremiumMember
02/23/24 3:55 PM
profile icon
axelvento Free
11/14/23 9:16 AM
profile icon
Renee PremiumMember
11/01/23 6:14 PM
profile icon
Monksdream PremiumMember
09/30/23 1:21 PM
profile icon
Monksdream PremiumMember
09/13/23 1:29 PM
profile icon
Monksdream PremiumMember
09/06/23 2:59 PM
profile icon
Investopotia Free
01/31/22 11:56 AM
profile icon
EagleD Free
12/26/20 4:16 PM
profile icon
EagleD Free
12/17/20 7:21 PM
profile icon
EagleD Free
09/26/20 8:48 PM
profile icon
EagleD Free
09/14/20 6:30 PM
profile icon
Renee PremiumMember
08/24/20 10:33 AM
profile icon
tykundegex Free
01/03/19 5:01 PM
profile icon
BioSpecialist Free
09/21/17 10:27 AM

Medicenna Therapeutics Corp (MDNAF) RSS Feed

Followers
5
Posters
8
Posts (Today)
0
Posts (Total)
18
Created
09/18/17
Type
Free
Moderators
Here is a very attractive and brutally undervalued canadian company called Medicenna (MDNA.TO) which is listed since March thats why its also undicovered . This Cancer Play has a Phase 2 trial in recurrent Glioblastoma ongoing a $650 Million Market , they expect to complete enrollment by year end and to report results in early Q1 2018 . If the results are positive then they can file for accelerated approval in 2H 2018 and this makes this company with a terrible low valuation of only C$ 36 Million a super attractive opportunity which has 10 bagger potential easily on positive phase 2 results in Q1 2018 and FDA approval .Please do your own DD and realize the mega potential .GL


Medicenna Therapeutics (MDNA.TO)

Market Cap C$36 Million
Cash : C$ 20 Million << enough untill Q1 2019
Price : $1.50

Shares Out: 24.3 Million ( 15.5 Million shares held by Insider alone )


Medicenna Therapeutics (TSXV: MDNA) CEO: Our Drug Has Potential for Phase 2 Approval
https://smallcappower.com/videos/companies-to-watch/medicenna-therapeutics-tsxv-mdna/



New Presentation
http://s21.q4cdn.com/710416940/files/doc_presentations/2017/Medicenna-Corporate-Presentation-Q3-2017.pdf


Fact Sheet
http://s21.q4cdn.com/710416940/files/doc_downloads/fact_sheet/Medicenna-FS-Q1-2017-v2.pdf

Insider Ownership :

Aries Biologics, Inc. 5 500 000
Rosemina Merchant 5 050 000
Fahar Merchant 5 050 000
Elizabeth Williams 5 300
Chandrakant J. Panchal, PhD 1 000
Trevor P. Wong-Chor 714



\


\




 
Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
New Post